W. Frank An
YOU?
Author Swipe
View article: A six‐repeat <scp>PPR</scp> protein <scp>WPR</scp> directly binds target <scp>RNAs</scp> and coordinates chloroplast <scp>RNA</scp> processing via dual recruitment of <scp>MORF1</scp> , <scp>MORF8b</scp> , and <scp>CAF2</scp> proteins in rice
A six‐repeat <span>PPR</span> protein <span>WPR</span> directly binds target <span>RNAs</span> and coordinates chloroplast <span>RNA</span> processing via dual recruitment of <span>MORF1</span> , <span>MORF8b</span> , and <span>CAF2</span> proteins in rice Open
SUMMARY Pentatricopeptide repeat (PPR) proteins are key regulators of organelle RNA metabolism in plants, yet their precise mechanisms in chloroplast RNA processing remain unclear. Here, we identify WPR, a unique P‐type PPR protein in rice…
View article: The efficacy and safety of robotic, laparoscopic, and open surgery for pediatric choledochal cysts: a systematic review and network meta-analysis
The efficacy and safety of robotic, laparoscopic, and open surgery for pediatric choledochal cysts: a systematic review and network meta-analysis Open
RO is effective and safe for the management of CC. The opportunity to convert to open surgery should not be missed due to fears of excessive bleeding or increased postoperative bile leakage.
View article: The function of GPCRs in different bone cells
The function of GPCRs in different bone cells Open
G protein-coupled receptors (GPCRs) are recognized as critical therapeutic targets in bone disorders, owing to their multifaceted regulatory roles across diverse bone cell lineages. This review systematically catalogs GPCR expression and f…
View article: Magnetic Supramolecular Hydrogel in Situ Polymerization with Acrylated β‐Cyclodextrin for the Efficient Adsorption of Pollutants
Magnetic Supramolecular Hydrogel in Situ Polymerization with Acrylated β‐Cyclodextrin for the Efficient Adsorption of Pollutants Open
Supramolecular hydrogels have significant research implications for the environmental application of dyes and bisphenols wastewater. Herein, a magnetic Fe 3 O 4 ‐P(AAm‐AMPS‐CDA) supramolecular hydrogel is reported, which is constructed by …
View article: 479 Fc-competent fully human anti-TIGIT blocking monoclonal antibodies demonstrated potent anti-tumor efficacy in preclinical models
479 Fc-competent fully human anti-TIGIT blocking monoclonal antibodies demonstrated potent anti-tumor efficacy in preclinical models Open
Background T cell immunoreceptor with Ig and ITIM domain (TIGIT) is a high-affinity inhibitory receptor that competes with CD226 for binding to CD155. TIGIT inhibits the activity of both T and NK cells, thereby dampening the immune respons…
View article: 1152 DM001: A novel bispecific ADC targeting TROP2 and EGFR with potent anti-tumor efficacy in PDX models
1152 DM001: A novel bispecific ADC targeting TROP2 and EGFR with potent anti-tumor efficacy in PDX models Open
Background EGFR is a promising therapeutic target expressed on multiple tumor cell types. While single-targeting antibodies and ADCs have been explored, limitations encountered with current therapies, such as drug resistance and lack of cy…
View article: 1175 YH006, a fully human Treg-depleting CTLA-4×OX40 bispecific antibody, demonstrates superior preclinical efficacy and favorable developability
1175 YH006, a fully human Treg-depleting CTLA-4×OX40 bispecific antibody, demonstrates superior preclinical efficacy and favorable developability Open
Background Tumor-infiltrating regulatory T (Treg) cells aid the development and progression of tumors by inhibiting the anti-tumor immune response. This immunosuppressive effect often leads to resistance against current immunotherapies for…
View article: 356 Preclinical application of a fully human TCR-mimic antibody developed to target NY-ESO-1/HLA-A02
356 Preclinical application of a fully human TCR-mimic antibody developed to target NY-ESO-1/HLA-A02 Open
Background A popular target for tumor vaccines and TCR-T cell therapy is NY-ESO-1, a cancer testis antigen (CTA) family member. NY-ESO-1 is expressed at varying degrees in several cancers such as synovial sarcoma, neuroblastoma, melanoma, …
View article: 1164 BSA01, a bispecific antibody-drug conjugate targeting EGFR and membrane-bound MUC-1-C, exhibits anti-tumor efficacy <i>in vivo</i>
1164 BSA01, a bispecific antibody-drug conjugate targeting EGFR and membrane-bound MUC-1-C, exhibits anti-tumor efficacy <i>in vivo</i> Open
Background EGFR and the surface glycoprotein MUC-1 are commonly co-expressed in several malignancies, including esophageal squamous cell carcinomas, non-small cell lung cancers (NSCLC), and triple-negative breast cancers. To overcome limit…
View article: 1150 DM005, an EGFR × MET bispecific antibody-drug conjugate, showed robust anti-tumor activity in PDX models
1150 DM005, an EGFR × MET bispecific antibody-drug conjugate, showed robust anti-tumor activity in PDX models Open
Background Bispecific antibodies (BsAb) that target dual tumor-associated antigens can invoke synergistic effects between two signaling pathways, increase target tissue specificity, and reduce systemic toxicity. Combining antibody-mediated…
View article: 1163 A novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, BCG033, demonstrates preclinical efficacy against triple-negative breast cancer xenografts
1163 A novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, BCG033, demonstrates preclinical efficacy against triple-negative breast cancer xenografts Open
Background Patients with metastatic triple-negative breast cancer (TNBC) have low rates of overall survival, indicating the need to develop novel treatments. Although the TROP2-targeting ADC sacituzumab govitecan was recently granted accel…
View article: 1165 Preclinical evaluation of fully human bispecific antibody-drug candidates targeting HER3 and the juxtamembrane region of MUC1
1165 Preclinical evaluation of fully human bispecific antibody-drug candidates targeting HER3 and the juxtamembrane region of MUC1 Open
Background Single-targeting immunotherapeutic agents for the tumor-associated antigens HER3 and MUC1 have shown limited efficacy in the clinic.1–4 Notably, as MUC1 can undergo auto-proteolysis, the efficacy of drugs targeting the MUC1-N re…
View article: 1153 BCG022: a HER3×MET bispecific antibody-drug conjugate (BsADC) targeting key mechanisms of bypass resistance in multiple tumor types
1153 BCG022: a HER3×MET bispecific antibody-drug conjugate (BsADC) targeting key mechanisms of bypass resistance in multiple tumor types Open
Background HER3 is a unique EGFR family member that plays a role in tumor progression, and its expression can act as a bypass mechanism for EGFR and HER2-targeted therapies, resulting in drug resistance. In addition to HER3, MET has also b…
View article: Discovery of Selective Inhibitors of Endoplasmic Reticulum Aminopeptidase 1
Discovery of Selective Inhibitors of Endoplasmic Reticulum Aminopeptidase 1 Open
ERAP1 is an endoplasmic reticulum-resident zinc aminopeptidase that plays an important role in the immune system by trimming peptides for loading onto major histocompatibility complex proteins. Here, we report discovery of the first inhibi…
View article: Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects
Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects Open
The mood stabilizer lithium, the first-line treatment for bipolar disorder, is hypothesized to exert its effects through direct inhibition of glycogen synthase kinase 3 (GSK3) and indirectly by increasing GSK3's inhibitory serine phosphory…
View article: Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors
Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors Open
RAD52 is a member of the homologous recombination (HR) pathway that is important for maintenance of genome integrity. While single RAD52 mutations show no significant phenotype in mammals, their combination with mutations in genes that cau…